Portfolio and technology meetings

Pharmaceutical companies with large portfolios can attend free, virtual meetings with European Medicines Agency (EMA). These meetings address development issues and anticipate future scientific and regulatory needs. They aim to support successful product portfolio development.
HumanVeterinaryInnovation

Pharmaceutical companies with large medicinal product portfolios can apply to attend a portfolio and technology meeting (PTM) with EMA.

These meetings can:

  • identify any issues impacting the progress of product portfolios and assist successful development;
  • capture innovative and disruptive technologies;
  • anticipate the scientific and regulatory expertise needed to assess future applications.

They are free-of-charge and held virtually.

How to apply

EMA invites large pharmaceutical companies to apply for a portfolio and technology meeting taking place in the second half of 2026.

They can apply by filling out the following application form:

The deadline to submit applications is 30 April 2026. 

EMA will review the request and advise on the next steps by the end of May 2026.

For any questions, please contact:

What to do if invited

You can find an overview of the application timeline below.

  1. Applying for a meeting

    The applicant completes the application form.

    EMA reviews it and confirms whether the meeting is granted within 6 weeks.

  2. Sending the briefing document

    If the meeting is granted, EMA asks the applicant to complete and send a briefing document 4 to 6 weeks in advance via Eudralink.

    The briefing document template is available in the section right below.

  3. Sending a presentation

    The applicant provides a presentation one week before the meeting containing the list of the participants.

  4. Preparing the draft meeting report

    Applicants prepare a draft meeting report within 10 working days outlining the topics discussed and outcomes. They should send it via Eudralink to EMA.

    The meeting report template is available in the section right below.

  5. Finalisation of the meeting report

    EMA reviews the draft meeting report within 10 working days and provides the final version via Eudralink.

Documents

The required templates are available below.

Frequently asked questions

Portfolio and Technology Meetings (PTM) cover topics related to the development of innovative medicines.

They aim to:

  • identify issues affecting the progress of product portfolios;
  • assist the successful development of medicines;
  • anticipate scientific and regulatory expertise needs.

Applicants can only submit applications when the call for expression of interest is open.

Participants are subject matter experts from EMA. EMA provides the preliminary list of EMA participants 2-3 days before the meeting.

EMA typically schedules these meetings in the afternoon to suit various time zones. 

The meetings are virtual and last 90 minutes. There is no limit to the number of participants.

Applicants provide the topics for discussion by completing an online application form. This can be done when the call for expression of interest is open on the EMA website.

In principle, no. Additionally, same discussion points should be included in the briefing document (BD) and in the presentation provided for the meeting.

However, applicants can request to modify some topics or add new ones, which EMA will assess individually.

Note, EMA grants meetings based on the topics provided in the online application form. The meeting date is arranged based on the selected members of the expert panel for the proposed topics.

The following topics are examples of topics discussed at these meetings:

  • Complex clinical trial methodologies
  • Digital technologies, including artificial intelligence and machine learning
  • Innovative manufacturing methods
  • Nanotechnologies
  • Policy-related
  • Smart materials and synthetic biology
  • New approach methodologies (NAMs)
  • Innovative methods for medicines in pregnancy and breastfeeding
  • Combination products and trials
  • Platform technologies for new medicines

 

In this section of the application form, EMA would like to gather applicants’ perspectives on topics of particular interest to regulators, regardless of the proposed topics for discussion during the PTM.

EMA will consider the provided information in a holistic manner and use it to support horizon scanning, resource planning, and to future-proof the regulatory network.

If, for any reasons, applicants choose not to reply, EMA kindly asks for a brief explanation.

The views expressed in the meetings are the opinions of participants and may not reflect the opinions of EMA’s scientific committees.

Participants should interpret the answers provided as preliminary scientific and regulatory considerations of the information presented. These answers do not constitute regulatory guidance or review recommendations for any applications.

We recommend phrasing your topics according to the examples provided below:

  • What is the experts’ opinion on…
  • Do the participants have comments / suggestions with regard to…
  • We would like to discuss suggestions with regard to…
  • Would the participants have proposal with regard to…
  • Should any other guidelines and/or guidance be considered?

EMA provides the applicant with the meeting report template including the final list of participants.

EMA requests the applicant to draft the meeting report within 10 working days, detailing the topics discussed and the outcome of the discussions. 

The draft meeting report is circulated for comments to EMA participants, reviewed by the coordinator and the final version of the meeting report is sent via EudraLink back to applicants within 10 working days.

Page update history

An update log is available to show the date and summary of changes to this webpage. It does not include updates to linked documents or minor edits like typos or broken link fixes.

The tracking of updates begins in March 2026.

10 March 2026

'How to apply' section added

Share this page